Pulse Biosciences Reports Q1 Financials with $18.6M Net Loss and $14.6M Quarterly Cash Burn

summarizeSummary

Pulse Biosciences reported preliminary Q1 2026 financial results, including a net loss of $18.6 million and $14.6 million in cash used in operations, alongside updates on its clinical trials.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a preliminary net loss of $18.6 million on $0.4 million in product revenue for the first quarter ended March 31, 2026.

• Cash Position and Burn

  Ended Q1 2026 with $68.3 million in cash and cash equivalents, having used $14.6 million in operating activities during the quarter, indicating a runway of approximately 4.6 quarters.

• Clinical Trial Progress

  Reaffirmed accelerated enrollment for the NANOPULSE-AF trial (completion by early-Q4 2026) and NANOCLAMP-AF trial (completion by end of H1 2027).

auto_awesomeAnalysis

This 8-K provides official details on Pulse Biosciences' first-quarter financial performance, confirming a significant cash burn of $14.6 million, which reduces its cash and equivalents to $68.3 million. While the company has an existing ATM program and shelf registration for future capital raises, this burn rate implies a cash runway of approximately 4.6 quarters. The filing also reiterates previously announced accelerated enrollment timelines for its NANOPULSE-AF and NANOCLAMP-AF clinical trials, which are critical to its strategic focus on electrophysiology. Investors should monitor the company's cash management and progress in these pivotal trials.